Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cellink in conjunction with the acquisition of cytena
Mandate

Vinge advises Cellink in conjunction with the acquisition of cytena

August 05, 2019 M&A

Vinge has advised Cellink AB (publ) in connection with the acquisition of all shares in cytena GmbH. cytena is a life science company which focuses on single cell technologies.

Cytena was established in 2014 from the Institute for Microsystems Technology at the University of Freiburg and primarily sells solutions for the handling of biological cells. The purchase price amounts to MEUR 30.25, corresponding to MSEK 323, and is paid with 1/3 in cash and 2/3 in newly issued Cellink shares. Cellink will convene an extraordinary general meeting which will resolve upon the directed issue of shares to the sellers of cytena.

Vinge’s team primarily consisted of Anders Strid, Daniel Lennartsson Anderås, Alexander Lindeberg and Adam Loewenstein.

Related

Vinge advises Fortinova Fastigheter AB (publ) on its first SEK 200 million green bond issue

 Vinge has advised Fortinova Fastigheter AB (publ) (“Fortinova”) on the company’s first issue of senior unsecured green bonds in an aggregate principal amount of SEK 200 million, under a framework of up to SEK 600 million. Nordea, acted as sole bookrunner in connection with the bond issue.
September 18, 2026

Vinge advises Morrow Bank AB (publ) in connection with the bank’s sale of parts of MedMera Bank and the sale of NPL portfolios

 Vinge has advised Morrow Bank AB (publ) in connection with the divestment of parts of MedMera Bank’s operations to a leading global credit investment firm. The divestment is structured as a sale of shares and priced at a premium of approximately SEK 90 million above equity value as per the completion date. The transaction includes parts of MedMera’s banking operations such as IT infrastructure, organisation and management, whilst Morrow Bank retains MedMera’s performing loans, deposits, customers, the MedMera brand, the Coop partnership agreement as well as key personnel.
September 15, 2026

Vinge advises HealthCap in conjunction with its investment in AMRA Medical

 HealthCap is investing in AMRA Medical AB, a company that analyses whole-body MRI images to classify and quantify an individual’s muscle and fat tissue throughout the body and places this in relation to human health and disease.
September 15, 2026